DNDi - NewsLetter


HOME
ABOUT DNDi EDITORIAL: "Key Challenges for Successful Partnerships" CALENDAR HOW YOU CAN HELP DNDi?
DNDi's Malaria Project: A Model for Innovative Partnerships? Fighting Malaria in the Legal Amazon, Brazil ASMQ in a Nutshell ASAQ: a new Business Model for a "Big Pharma" ASMQ: a Great Public-Private, Intercontinental Partnership Why Lead Platforms are Crucial to Boost Innovation for Neglected Diseases Asian Region Makes Use of its Biodiversity to Identify New Bioactive Molecules Our moral responsibility to address Public Health Issues Four Characteristics For Partnership Paving the Way to Win-Win Partnerships DNDi R&D Projects-2008 Outlook Synergise Efforts with Anacor, GSK, IRD, Eskitis, UNC, and Intitut Pasteur Korea. Operational Challenges: Clinical Trial Partnerships in Africa LEAP: 4 Years and Going Strong... Concentrated HAT Platform Efforts in the 5 Most Affected Countries Advances at the DNDi Regional Support Office KEMRI, Nairobi Actions to Increase Awareness and Visibility in the Asian Region DNDi's Launch of ASMQ in Rio de Janeiro DNDi Project Collaboration in Japan DNDi in DRC brings Regular Support to the Clinical Trials From Discovery to Clinical Trials in India DNDi Strengthens North American Presence DNDi Joins Scientists Without Borders^SM Fexinidazole: A Rediscovered Compound Progresses as a Preclinical Drug Candidate for HAT Neglected by Everybody: PLoS NTD Publishes Media Analysis on Neglected Diseases DNDi Participates at International Meeting on Chagas Disease DNDi Awarded by the French Societé de Pathologie Exotique DNDi Receives Goodwin Award for Its Social Entrepeneurial Approach for the Most Neglected Diversifying Sources of Funding News from Donors IGWG: An Important Step Towards Boosting Innovation Contact DNDi

DNDi's Malaria Project: A Model for Innovative Partnerships? No single State, organisation, company, or community can meet malaria's challenges alone. Cooperation and coordination are important elements to ensure an effective and rapid response to control malaria. In line with DNDi's goals to meet the needs of people most threatened by neglected diseases, two antimalarial drugs have been delivered within the multi-partner Fixed-Dose, Artesunate-Based Combination Therapies (FACT) Project, which was created in 2002 under the umbrella of MSF and then transferred to DNDi in 2003 in coordination with the UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases (TDR). As Executive Director of DNDi, Dr. Bernard Pécoul offers his take on how partnership is so valuable in addressing urgent needs for those affected by malaria. read more
Why Lead Platforms are Crucial to Boost Innovation for Neglected Diseases Drug discovery is very much a 'numbers game'. To give a couple of examples: 1 • The chemical space inhabited by most drugs could be described as relatively small molecules (less than 500 Daltons) which contain some of the following elements: carbon, oxygen, phosphorus, sulfur, nitrogen, chlorine, fluorine, bromine... read more Operational Challenges: Clinical Trial Partnerships in Africa Developing new treatments for people suffering from sleeping sickness (HAT) or visceral leishmaniasis (VL) is a long and difficult process, especially when clinical trials are carried out in rural areas in Africa where health infrastructure is limited or non-existent... read more Fexinidazole: A Rediscovered Compound Progresses as a Preclinical Drug Candidate for HAT Neglected by Everybody: PLoS NTD Publishes Media Analysis on Neglected Diseases DNDi Participates at International Meeting on Chagas Disease DNDi Awarded by the French Societé de Pathologie Exotique DNDi Receives Goodwin Award for Its Social Entrepeneurial Approach for the Most Neglected		Paving the Way to Win-Win Partnerships The DNDi mission is to develop new therapies for the most neglected diseases as a response to the blatant medical needs of patients belonging to populations amongst the poorest in the world. Because these patients lie completely outside of the global pharmaceutical market, the traditional profit-based approach cannot be implemented, resulting in the absence of any significant efforts to develop drugs for diseases such as sleeping sickness or leishmaniasis. read more Advances at the DNDi Regional Support Office KEMRI, Nairobi Actions to Increase Awareness and Visibility in the Asian Region DNDi's Launch of ASMQ in Rio de Janeiro DNDi Project Collaboration in Japan DNDi in DRC brings Regular Support to the Clinical Trials From Discovery to Clinical Trials in India DNDi Strengthens North American Presence DNDi Joins Scientists Without Borders^SM Diversifying Sources of Funding News from Donors IGWG: An Important Step Towards Boosting Innovation

Published by Drugs for Neglected Diseases Initiative - 15 Chemin Louis-Dunant 1202 Geneva Switzerland - Photo credits: DNDi unless otherwise stated - Editor: Sadia Kaenzig - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.dndi.org